Research Director, Docent Markku Lhteenvuo from the University of Eastern Finland, said: Because this is a registry-based study, we cannot determine exactly why or how these medications affect mood symptoms, but the association was quite strong
2 Department of Endocrinology, SANKO University Faculty of Medicine, Gaziantep, Turkey Correspondence: Nimet Ylmaz, Department of Gastroenterology, SANKO University Faculty of Medicine, Gaziantep, Turkey, Email [email protected] Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1/GIP receptor agonists are highly effective agents for the treatment of type 2 diabetes and obesity
Since tirzepatide already delays gastric emptying, high fat foods that amplify this effect may worsen digestive upset
Besides the CREDENCE trial, other non-empagliflozin trials also failed to show significant changes.12,19 Trials of non-empagliflozin SGLT2 inhibitors investigating mortality endpoints are needed to fill in the evidence gap
[DOI] [PMC free article] [PubMed] [Google Scholar] 3.Drucker D.J
